CompletedPhase 2NCT00410826
Cisplatin and Radiation Therapy With or Without Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Studying Nasopharyngeal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of Washington
- Principal Investigator
- Renato Martins, MD, MPHFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
- Intervention
- erlotinib hydrochloride(drug)
- Enrollment
- 204 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2006
Study locations (9)
- Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
- University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, United States
- University of New Mexico Health Science CCOP, Albuquerque, New Mexico, United States
- University of North Carolina, Chapel Hill, North Carolina, United States
- New Hanover Radiation Oncology Center, Wilmington, North Carolina, United States
- Medical University of South Carolina, Charleston, South Carolina, United States
- University of Tennessee Cancer Institute-Boston Cancer Group PLC, Memphis, Tennessee, United States
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
- Multicare Health System, Tacoma, Washington, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00410826 on ClinicalTrials.govOther trials for Nasopharyngeal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06980038Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07584499Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid TumorsSun Yat-sen University
- RECRUITINGPHASE2NCT07362979Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal CarcinomaSun Yat-sen University
- RECRUITINGPHASE3NCT07459296Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPCFirst Affiliated Hospital of Guangxi Medical University
- RECRUITINGNANCT06796270Hypofractionated Radiotherapy for Nasopharyngeal CarcinomaThe Second Affiliated Hospital of Hainan Medical University
- RECRUITINGPHASE2NCT06059261Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.Chongqing University Cancer Hospital
- RECRUITINGNCT07376603IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk FeaturesQiaojuan Guo
- RECRUITINGPHASE3NCT07340515Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III TrialMan Hu